首页> 外文期刊>Systematic Reviews >Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis
【24h】

Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis

机译:非个体顺势疗法的随机,双盲,安慰剂对照试验:系统评价和荟萃分析

获取原文
       

摘要

Background A rigorous systematic review and meta-analysis focused on randomised controlled trials (RCTs) of non-individualised homeopathic treatment has not previously been reported. We tested the null hypothesis that the main outcome of treatment using a non-individualised (standardised) homeopathic medicine is indistinguishable from that of placebo. An additional aim was to quantify any condition-specific effects of non-individualised homeopathic treatment. Methods Literature search strategy, data extraction and statistical analysis all followed the methods described in a pre-published protocol. A trial comprised ‘reliable evidence’ if its risk of bias was low or it was unclear in one specified domain of assessment. ‘Effect size’ was reported as standardised mean difference (SMD), with arithmetic transformation for dichotomous data carried out as required; a negative SMD indicated an effect favouring homeopathy. Results Forty-eight different clinical conditions were represented in 75 eligible RCTs. Forty-nine trials were classed as ‘high risk of bias’ and 23 as ‘uncertain risk of bias’; the remaining three, clinically heterogeneous, trials displayed sufficiently low risk of bias to be designated reliable evidence. Fifty-four trials had extractable data: pooled SMD was –0.33 (95% confidence interval (CI) –0.44, –0.21), which was attenuated to –0.16 (95% CI –0.31, –0.02) after adjustment for publication bias. The three trials with reliable evidence yielded a non-significant pooled SMD: –0.18 (95% CI –0.46, 0.09). There was no single clinical condition for which meta-analysis included reliable evidence. Conclusions The quality of the body of evidence is low. A meta-analysis of all extractable data leads to rejection of our null hypothesis, but analysis of a small sub-group of reliable evidence does not support that rejection. Reliable evidence is lacking in condition-specific meta-analyses, precluding relevant conclusions. Better designed and more rigorous RCTs are needed in order to develop an evidence base that can decisively provide reliable effect estimates of non-individualised homeopathic treatment.
机译:背景以前没有关于非个体顺势疗法的随机对照试验(RCT)的严格系统综述和荟萃分析。我们检验了零假设,即使用非个体化(标准化)顺势疗法药物的主要治疗结果与安慰剂没有区别。另一个目的是量化非个体顺势疗法的任何特定条件的影响。方法文献搜索策略,数据提取和统计分析均遵循预发布协议中描述的方法。如果某项试验的偏倚风险低或在一个特定的评估范围内不清楚,则该试验包括“可靠证据”。 “效果大小”报告为标准均值差(SMD),并根据需要对二分数据进行了算术转换; SMD阴性表示有利于顺势疗法。结果在75个合格的RCT中代表了48种不同的临床状况。有49项试验被归类为“有偏见的高风险”,有23项被归类为“不确定的有偏见的风险”;其余三项临床异质性试验显示的偏倚风险足够低,可以用作可靠的证据。五十四项试验具有可提取的数据:汇总的SMD为–0.33(95%置信区间(CI)–0.44,–0.21),在对出版偏倚进行调整后,衰减至–0.16(95%CI –0.31,–0.02)。有可靠证据的三项试验得出的SMD均无统计学意义:–0.18(95%CI –0.46,0.09)。没有哪一项临床条件的荟萃分析包括可靠的证据。结论证据的质量很低。所有可提取数据的荟萃分析都会导致我们的原假设被拒绝,但是对一小部分可靠证据的分析并不支持这种拒绝。在条件相关的荟萃分析中缺乏可靠的证据,无法排除相关结论。需要更好的设计和更严格的RCT,以建立证据,从而可以果断地提供非个体顺势疗法的可靠疗效估计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号